Toxicities of Human Recombinant Interferon-α2 in Patients with Advanced Prostate Carcinoma
- 1 December 1986
- journal article
- research article
- Published by Mary Ann Liebert Inc in Journal of Interferon Research
- Vol. 6 (6) , 713-715
- https://doi.org/10.1089/jir.1986.6.713
Abstract
Nine patients with hormone-resistant prostate carcinoma were treated with subcutaneous injection of recombinant human interferon-α2 (rHuIFN-α2), 5-10 χ 106 U/m2, three times a week. One patient had a mixed clinical response with reduction of bone pain. The study was closed due to intolerable grade III and IV toxicities including weight loss (8/9), fatigue/malaise (7/9), central nervous system toxicity (4/9), leukopenia (3/9), and uncontrollable nausea and vomiting (2/9). These toxicities resulted in deterioration of performance status. It is concluded that rHuIFN-α2, at least at the dose and schedule studied, should not be used for the treatment of patients with hormone-resistant prostate carcinoma.Keywords
This publication has 10 references indexed in Scilit:
- Phase II study of recombinant alpha-2 interferon in resistant multiple myeloma.Journal of Clinical Oncology, 1985
- Progress toward therapeutic application of interferons, 1979–1983Cancer, 1984
- Recombinant Alpha-2 Interferon Therapy for Kaposi's Sarcoma Associated with the Acquired Immunodeficiency SyndromeAnnals of Internal Medicine, 1984
- Comparison of the biologic effects of two recombinant human interferons alpha (rA and rD) in humans.Journal of Clinical Oncology, 1984
- Toxicity and response criteria of the Eastern Cooperative Oncology GroupAmerican Journal of Clinical Oncology, 1982
- A phase II evaluation of adriamycin and cis-platinum in hormone resistant prostate cancerCancer, 1982
- Human leukocyte interferon (HuIFN-α): Potent endorphin-like opioid activityBiochemical and Biophysical Research Communications, 1981
- Systemic Treatment of Advanced Prostatic Cancer: Development of a New System for Defining ResponseJournal of Urology, 1981